Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade.

CONCLUSION: irPR features are consistent across tumor types and treatment settings. Standardized, pan-tumor immune-mediated pathologic response criteria (irPRC) are defined and associated specimen-handling considerations are described. Future, prospective studies are merited to validate irPRC in larger datasets and to associate pathologic features with long-term patient outcomes.
PMID: 31672770 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - October 30, 2019 Category: Cancer & Oncology Authors: Stein JE, Lipson EJ, Cottrell TR, Forde PM, Anders RA, Cimino-Mathews A, Thompson ED, Allaf ME, Yarchoan M, Feliciano J, Wang H, Jaffee EM, Pardoll DM, Topalian SL, Taube JM Tags: Clin Cancer Res Source Type: research